



NewLink Genetics Corporation  
Investor Relations Department  
2503 South Loop Drive  
Ames, IA 50010  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## Company Profile

---

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [\[ View all \]](#)

---

*Jan 8, 2018*

[NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors](#)

*Dec 21, 2017*

[NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

*Nov 27, 2017*

[NewLink Genetics to Participate in Upcoming Investor Conference](#)

*Nov 20, 2017*

[NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children](#)

*Nov 14, 2017*

[NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer](#)

## Financials [\[ View all \]](#)

---

[Third Quarter Financial Results](#)

*Mar 6, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 3, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 3, 2017*

[Quarterly Report \(10-Q\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)